| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/12/2013 | EP2600897A2 Methods and compositions for the inhibition of fructokinase |
| 06/12/2013 | EP2600896A2 Treating breast cancer with anti-il-19 antibody |
| 06/12/2013 | EP2600895A1 Chronic lymphocytic leukemia (cll) biomarkers |
| 06/12/2013 | EP2600894A1 Modified hepatitis c virus proteins |
| 06/12/2013 | EP2600893A1 Inactivated varicella zoster virus vaccines, methods of production, and uses thereof |
| 06/12/2013 | EP2600892A2 Modified infectious laryngotracheitis virus (iltv) and uses thereof |
| 06/12/2013 | EP2600891A2 Protein fusion constructs possessing thrombolytic and anticoagulant properties |
| 06/12/2013 | EP2600890A1 Method of antigen loading for immunotherapy |
| 06/12/2013 | EP2600889A2 Anti-la antibodies and their use for immunotargeting |
| 06/12/2013 | EP2600882A1 Antibodies against 6-sulfo-lacnac-positive human dendritic cells, and their use |
| 06/12/2013 | EP2600878A2 Regulatory b cells and their uses |
| 06/12/2013 | CN1461310B ANtibodies that bind human interleukin-18 and methods of making and using |
| 06/12/2013 | CN103154251A Generation of virosome particles |
| 06/12/2013 | CN103154238A MDCK-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells |
| 06/12/2013 | CN103154036A Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin FC compositions |
| 06/12/2013 | CN103154035A Monoclonal antibodies against her2 |
| 06/12/2013 | CN103154034A Antibodies that bind human cd27 and uses thereof |
| 06/12/2013 | CN103154032A Antibodies to IL-1beta and IL-18, for treatment of disease |
| 06/12/2013 | CN103154031A Methods of treating psoriasis using il-17 antagonists |
| 06/12/2013 | CN103154030A Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
| 06/12/2013 | CN103154028A Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases |
| 06/12/2013 | CN103154026A Antibodies directed against il-17 |
| 06/12/2013 | CN103154025A Covalent diabodies and uses thereof |
| 06/12/2013 | CN103154021A Universal influenza a vaccines |
| 06/12/2013 | CN103154013A Trisaccharide derivates, and their use as adjuvants |
| 06/12/2013 | CN103153341A Chronic lymphocytic leukemia (Cll) biomarkers |
| 06/12/2013 | CN103153340A Treatment for neoplastic diseases |
| 06/12/2013 | CN103153339A Monoclonal antibodies against her2 epitope |
| 06/12/2013 | CN103153338A Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
| 06/12/2013 | CN103153337A Mucosal adjuvant composition |
| 06/12/2013 | CN103153336A Vaccine composition for controlling ectoparasite infestations |
| 06/12/2013 | CN103153292A Combination anti-cancer therapy |
| 06/12/2013 | CN103153289A Improved enteric active substance delivery |
| 06/12/2013 | CN103153284A Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| 06/12/2013 | CN103146734A Anti-burn and scald infection multiple organ failure Pseudomonas aeruginosa toxin vaccine |
| 06/12/2013 | CN103146708A Il-12/p40 binding proteins |
| 06/12/2013 | CN103146655A Seed selection of high-immunogenicity rabies virus fixed strain and application thereof in vaccine development |
| 06/12/2013 | CN103146654A Artificially weakened infectious bronchitis virus and application thereof |
| 06/12/2013 | CN103146653A Infectious bursal disease virus chick embryo fibroblast adapted strain H11 and application thereof |
| 06/12/2013 | CN103146627A Nonreactive multi-valence Edwardsiella tarda carrier live vaccine, and preparation method and application thereof |
| 06/12/2013 | CN103145854A Recombined Tbeta 4-BP5 fusion peptide, gene, engineering bacteria and application |
| 06/12/2013 | CN103145853A Recombined Talpha 1-BP5 fusion peptide, gene, engineering bacteria and application |
| 06/12/2013 | CN103145844A A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 06/12/2013 | CN103145842A Il-12/p40 binding proteins |
| 06/12/2013 | CN103145841A Il-12/p40 binding proteins |
| 06/12/2013 | CN103145840A Il-12/p40 binding proteins |
| 06/12/2013 | CN103145839A IL-12/P40 binding proteins |
| 06/12/2013 | CN103145838A IL-12/p40 binding proteins |
| 06/12/2013 | CN103145837A IL-12/P40 binding proteins |
| 06/12/2013 | CN103145836A Anti-myostatin single-chain antibody, and its coding gene, expression vector, recombinant transformant and application |
| 06/12/2013 | CN103145835A Anti-system ASC amino acid transporter 2 (ASCT2) antibody |
| 06/12/2013 | CN103145807A Hepatitis C virus (HCV) B-cell epitope peptide PUHI37 and application thereof |
| 06/12/2013 | CN103145806A Hepatitis C virus (HCV) B-cell epitope peptide PUHI26 and application thereof |
| 06/12/2013 | CN103145801A Anti-tumor CTL (Cytotoxic T Lymphocyte) epitope peptide from MTA1 (Tumor Metastasis Associated Antigen 1) and application thereof |
| 06/12/2013 | CN103143034A Recombinant vaccine against bluetongue virus |
| 06/12/2013 | CN103143032A Recombinant plasmid vaccine for treating hepatitis B and composition thereof |
| 06/12/2013 | CN103143017A VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| 06/12/2013 | CN103143016A Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing |
| 06/12/2013 | CN103143012A Traditional Chinese medicine composition and applications in preparation of porcine pseudorabies vaccine immunopotentiator |
| 06/12/2013 | CN103143011A Compositions and methods for treating neurological disorders |
| 06/12/2013 | CN103143010A Triad inactivated vaccine for newcastle disease and bird flu (H9 subtype) and escherichia coli disease and preparation method thereof |
| 06/12/2013 | CN103143009A Method for producing duck tembusu virus inactivated vaccines in large scale |
| 06/12/2013 | CN103143008A Duck tembusu virus living vaccine and preparation method thereof |
| 06/12/2013 | CN103143007A Method for preparing infectious bursal disease virus live vaccine by utilizing passage chicken embryo fibroblast |
| 06/12/2013 | CN103143006A Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use |
| 06/12/2013 | CN103143005A Application of polypeptide with LACK antigen Th2-type epitope in preparing medicine for preventing and treating autoimmune disease |
| 06/12/2013 | CN103143004A Survivin peptide vaccine |
| 06/12/2013 | CN103142599A Treatment of T-cell mediated diseases |
| 06/12/2013 | CN103142514A Lyophilized composition for injection containing thymalfasin and preparation method thereof |
| 06/12/2013 | CN102766603B Chicken Newcastle disease virus and its separation method |
| 06/12/2013 | CN102618503B Hybrid tumor cell strain 1D7 capable of secreting high neutralizing activity canine distemper virus monoclonal antibody |
| 06/12/2013 | CN102559606B A16 type strain of Coxsackie virus and application of the strain |
| 06/12/2013 | CN102533675B Recombinant newcastle disease virus LaSota vaccine strain for expressing nipah encephalitis virus F protein |
| 06/12/2013 | CN102532307B Method for preparing human immunoglobulin |
| 06/12/2013 | CN102397539B Duckling flavivirus disease inactivated vaccine and preparation method thereof |
| 06/12/2013 | CN102378814B Monoclonal antibody capable of binding to specific discontinuous epitope occurring in ad1 region of human cytomegalovirus gb glycoprotein, and antigen-binding fragment thereof |
| 06/12/2013 | CN102250852B Clone and expression of bovine recombinant alpha-1,3-galactoside transferase (GT) |
| 06/12/2013 | CN102210862B Livin-based immune-stimulating complex, preparation method thereof and application thereof |
| 06/12/2013 | CN102206255B Sequences of mutants of Tat protein of human immunodeficiency virus type I and use thereof |
| 06/12/2013 | CN102178946B Application of baby hamster kidney(BHK)-21 cell serum-free suspension culture technology in foot-and-mouth disease vaccine production |
| 06/12/2013 | CN102166351B H1N1 influenza A vaccine and application thereof |
| 06/12/2013 | CN102085368B Application of optimized TACI (Transmembrane Activator and CAML Interactor)-Fc fusion protein in preparation of medicaments for treating systemic lupus erythematosus |
| 06/12/2013 | CN102080074B Construction and application of porcine circovirus type II-porcine mycoplasma pneumoniae expressing strains |
| 06/12/2013 | CN101861163B Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods |
| 06/12/2013 | CN101768575B Construction of recombinant rabies virus of double-expression G gene and biological property analysis thereof |
| 06/12/2013 | CN101688229B Treatment method using EGFR antibodies and SRC inhibitors and related formulations |
| 06/12/2013 | CN101687035B Novel compounds |
| 06/12/2013 | CN101668770B 疫苗 Vaccine |
| 06/12/2013 | CN101588817B Fully human high yield production system for improved antibodies and proteins |
| 06/12/2013 | CN101573135B Canine lyme disease vaccine |
| 06/12/2013 | CN101547705B Compositions and methods for treating a neoplasm |
| 06/12/2013 | CN101466737B Targeted binding agents directed to uPAR and uses thereof |
| 06/12/2013 | CN101448858B Combinatorial therapy involving alpha5beta1 antagonists |
| 06/12/2013 | CN101437852B Anti-TAT226 antibodies and immunoconjugates |
| 06/12/2013 | CN101432307B Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| 06/12/2013 | CN101421303B Improved protofibril selective antibodies and the use thereof |
| 06/12/2013 | CN101395265B Mycobacterial SecA2 mutants |
| 06/12/2013 | CN101374551B Glycolipid adjuvant compositions |
| 06/12/2013 | CN101287492B Anti-glypican-3 antibody |
| 06/12/2013 | CN101198623B Methods and compositions for modulating and detecting WISP activity |